Trial Profile
A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Resveratrol (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK; Sirtris
- 26 Jan 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.